Stevanato Group (STVN) Q1 2026: GLP-1 Revenue Jumps to 22%, Cartridge Capacity Fully Booked
Stevanato’s Q1 saw high-value solutions and GLP-1 demand drive segment outperformance, even as engineering lagged on order intake. The company’s strategic pivot toward pre-fillable syringes and cartridges is accelerating, with cartridge capacity now fully booked for 2026 and new lines in the pipeline. Margin pressures from depreciation, FX, and tariffs were managed, but engineering backlog remains a key watchpoint for the second half.
Summary
- GLP-1 Demand Reshapes Mix: Injectable GLP-1 products now comprise over one-fifth of revenue, anchoring growth visibility.
- Cartridge Capacity Fully Booked: Conversion of vial lines to cartridges signals agile capital deployment to meet surging biologics demand.
- Engineering Segment Still Lags: Margin gains offset by slow order flow; backlog rebuild is critical for recovery.
Business Overview
Stevanato Group is a global supplier of drug containment, delivery, and diagnostic solutions, primarily serving the biopharmaceutical industry. The company’s core segments are Biopharmaceutical and Diagnostic Solutions (BDS), which includes pre-fillable syringes, cartridges, and vials, and the Engineering segment, which provides assembly and inspection equipment. Revenue is generated through the sale of high-value solutions—such as ready-to-use (RTU) syringes and cartridges—and standard products, with an increasing emphasis on biologics and injectable therapies.
Performance Analysis
Q1 2026 results reflected strong execution in BDS, with segment revenue up double digits and high-value solutions accounting for nearly half of companywide sales. GLP-1s, injectable therapies for diabetes and obesity, now represent 21% to 22% of total revenue, driving a 15% increase in biologics-related business. This mix shift underscores Stevanato’s position as a core supplier to the fastest-growing drug classes.
The Engineering segment posted a 31% revenue decline, as anticipated, but delivered margin improvement from operational optimization and a more selective project mix. Despite this, low backlog and slow order intake remain headwinds, with management focused on new business development and operational discipline. Margin expansion in BDS was offset by higher depreciation from capacity ramp-up, FX headwinds, and temporary tariff impacts, resulting in a modest gross margin increase at the group level.
- GLP-1s Anchor Growth: Predictable, contract-driven volumes provide multi-year visibility, with biosimilars and new indications expanding the addressable market.
- Cartridge Demand Outpaces Supply: RTU cartridge lines are fully booked for 2026, prompting rapid asset conversion and new capacity investments.
- Engineering Margin Recovery: Denmark’s operational turnaround improved profitability, but order conversion timing remains a concern.
Free cash flow turned positive as growth investments were balanced by strong operating cash generation. The capital allocation remains heavily weighted toward capacity expansion in high-value solutions, particularly in the U.S. and Italy.
Executive Commentary
"GLPs are a significant driver behind our current biologics growth. But nevertheless, you know, revenues in biologics relates to wide-ranging different areas, including MABs, biosimilars, mRNA applications, and other therapeutic areas like immunology, inflammatory, and rare disease."
Lisa Miles, Chief Communications Officer
"We are accelerating because we see a lot of demand. On top of it, as mentioned many times, we are investing in Latina for the new RTU technology that will be ready for commercial production by the beginning of 2027. We are serving two different types of customers here. We have much more flexibility in Piombino with the new converted line."
Marco DiLago, Chief Financial Officer
Strategic Positioning
1. GLP-1 and Biologics Tailwind
Stevanato’s leadership in injectable GLP-1 containment is a durable growth driver, with predictable contract volumes and a pipeline of biosimilars and new indications. The company’s share gains outpace the broader market, and management expects the injectable opportunity to remain dominant even as oral formulations expand.
2. Cartridge Capacity and Asset Flexibility
Rapid conversion of underutilized vial lines to cartridge production demonstrates engineering agility and capital discipline. With 2026 cartridge capacity fully booked and new RTU-400 high-speed lines coming online in 2027, Stevanato is positioned to capture the accelerating shift toward home-based, large-volume biologics delivery.
3. Engineering Segment Optimization
Profitability improvements in engineering stem from operational right-sizing, project mix, and cost control, especially in Denmark. However, the segment’s recovery hinges on accelerating order intake and rebuilding backlog, as customer decision cycles lengthen post-pandemic.
4. High-Value Solutions Mix Shift
High-value solutions now represent nearly half of total revenue, with further expansion expected as the company de-emphasizes non-core products and launches new service offerings like large-batch fill-and-finish (not for human use). This move up the value chain supports margin resilience.
5. Regulatory and Market Tailwinds
Annex 1 regulatory changes drive RTU adoption, as stricter contamination control standards favor Stevanato’s pre-sterilized formats. This provides a structural tailwind for both syringes and cartridges, supporting long-term demand visibility.
Key Considerations
The quarter reinforced Stevanato’s strategic commitment to biologics, cartridge flexibility, and operational discipline, but also surfaced execution watchpoints in engineering and cost management. Investors should weigh the following:
- GLP-1 Revenue Concentration: Exposure to a single drug class is high, but management sees sustained multi-year demand given broadening indications and biosimilar entry.
- Cartridge Supply-Demand Imbalance: Full utilization in 2026 and new lines in 2027 highlight both opportunity and the risk of supply constraints if demand accelerates further or if ramp-up is delayed.
- Engineering Order Lag: Margin gains are promising, but slow contract awards and backlog erosion could limit segment recovery if customer CapEx discipline persists.
- Cost and FX Pressures: Depreciation, energy, and FX weighed on margins, but management is actively passing costs through to customers and expects partial recovery of tariff impacts.
- Capital Allocation Discipline: Over 90% of CapEx targets high-value solutions, supporting future mix shift and reinforcing the move away from legacy offerings.
Risks
Key risks include: potential overdependence on GLP-1 demand, delays in engineering segment order conversion, and execution risk on new capacity ramp-up. Inflationary pressures and FX volatility remain margin headwinds, though cost pass-through mechanisms mitigate some exposure. Any significant change in regulatory or competitive dynamics, especially in biosimilars or orals, could alter the long-term growth trajectory.
Forward Outlook
For Q2 2026, Stevanato guided to:
- Low double-digit BDS segment growth, with engineering down around 10% YoY.
- First half revenue representing 45% of full-year expectations, with a stronger second half anticipated.
For full-year 2026, management maintained guidance:
- Revenue: $1.26B to $1.29B
- Adjusted EBITDA: $332M to $347M
- Adjusted diluted EPS: $0.59 to $0.63
Management highlighted:
- High-value solutions to reach 47% to 48% of annual revenue mix.
- Cartridge and syringe demand remain contractually visible, with new capacity rollouts on track.
Takeaways
Stevanato’s Q1 validates its strategic pivot to high-value biologics containment, but also underscores the pressure to rebuild engineering momentum and manage cost headwinds.
- Biologics and GLP-1s Are the Core Growth Engine: The company’s outsized share in GLP-1 and cartridge formats anchors multi-year visibility, but brings concentration risk.
- Engineering Must Convert Backlog to Sustain Recovery: Operational improvements are real, but order flow and customer CapEx cycles will dictate segment trajectory.
- Capacity Expansion and Mix Shift Drive Long-Term Upside: Investors should monitor the pace of cartridge ramp and the durability of high-value solution demand as the next phase unfolds.
Conclusion
Stevanato delivered a quarter that highlights its leadership in biologics containment and its ability to adapt capital to demand, while engineering remains a work in progress. The company’s mix shift and capacity plans provide a strong foundation, but execution on both commercial and operational fronts will determine the sustainability of its premium growth profile.
Industry Read-Through
Stevanato’s results provide a clear read-through for the broader drug delivery and injectable packaging sector: demand for GLP-1 and other biologics containment is accelerating, with capacity constraints likely to shape competitive dynamics through 2027. The shift toward home-based, large-volume biologics and regulatory-driven RTU adoption is a structural tailwind for suppliers with flexible assets and global reach. Engineering and automation providers serving pharma clients should expect longer sales cycles and more disciplined procurement, as customers balance CapEx with evolving treatment modalities. The sector’s winners will be those who can rapidly align capacity, quality, and regulatory compliance with shifting end-market demand.